Adaptilens is developing an accommodating intraocular lens (IOL) that adapts to the patient's surroundings, aiming to replicate the human lens as closely as possible.

Adaptilens

Grin Eye Care provides comprehensive eye care services, including cataract surgery, laser vision correction, and products like glasses and contacts. The company is self-described as dedicated to meeting all ophthalmology needs.

Grin Eye Care

SIEHT is a healthcare provider specializing in eye care services, including cataract surgery, LASIK vision correction, glaucoma treatment, and general eye exams.

SIEHT

Adaptilens is the only IOL that imitates the human eye’s natural lens. We are a team of ophthalmologists, cataract specialists, scientists, and engineers with a singular focus on improving the vision and quality of life of cataract patients. We are developing an accommodating IOL with novel polymers to give patients the ability to focus not just on a single distance but on objects near, far, and in between--without the help of glasses or contact lenses. To stay updated as our life-changing lens technology develops, follow us here or sign up for updates here: https://adaptilens.com/contact/

MassChallenge

Pillar VC

Accanto Partners

MassChallenge, one of Adaptilens’s earliest supporters, connects with CEO Liane Clamen, MD for an update. Check out the article below! 

https://lnkd.in/gCB9PNyx

Adaptilens Founder and CEO, Liane Clamen, MD, was honored to lead a roundtable discussion at a Harvard Innovation Labs' forum last week.

This week, the Boston Business Journal featured Dr. Liane Clamen, CEO of Adaptilens, highlighting her remarkable accomplishments in developing a best-in-class intraocular lens.

Adaptilens Founder and CEO Dr. Liane Clamen was honored to be invited to give a presentation on Adaptilens at the International Society of Presbyopia conference in Vienna. Adaptilens’ game-changing Accommodating Intraocular Lens will improve the quality of life of millions of people. #IOL #Ophthalmolgy #innovation

Adaptilens is proud to announce our Series A Financing of $17.5M led by Perceptive Advisors (Perceptive Xontogeny Venture Funds) with participation by Pillar VC, 380 Cap, and Accanto Partners. Together we are transforming the standard of care for cataract surgery.
https://lnkd.in/e7h86cha

Adaptilens CEO, Dr. Liane Clamen, will be co-hosting the 2023 Founder-led Biotech Tour! RSVP below to join her and other inspirational founders in Boston on November 7.

Metric
Company Name	Adaptilens	Grin Eye Care	SIEHT
Symbol
MSH ID	COM:ADAPTILENS	COM:GRINEYECARE	COM:SIEHT
Market	PRIVATE	PRIVATE	PRIVATE
Sector	Healthcare & Health Services	Healthcare & Health Services	Healthcare & Health Services
Industry	Medical Devices	Healthcare	Optometry
Country	US	US	US
Stage
Employee Count	7	11
Website	adaptilens.com	grineyecare.com	sieht.com
LinkedIn	adaptilens
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic	3.26K	419
Web Traffic Growth	10.82	-0.85
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

COM:ADAPTILENS

Adaptilens

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue